drugset / Trial / NCT04680195

Thalidomide in the Treatment of Chronic Radiation Proctitis With Intractable Bleeding

NCT04680195 ↗

NaSingle-groupOpen-labelTreatment

Summary

Chronic radiation proctitis (CRP) is the main secondary toxic injury after pelvic radiotherapy. Hematochezia is the most common symptom for more than 80% of CRP patients. Non-surgical treatment is the first choice to the treatment of CRP to avoid the occurrence of serious complications. Conventional oral medication for the treatment of bleeding CRP is very few and has little effect. At present, no oral medication has been found to significantly alleviate and control refractory bleeding of CRP. Therefore, it is an urgent problem to screen out a drug that is more effective, safe and highly compliant for the treatment of hemorrhagic CRP. Thalidomide has anti-inflammatory, immune regulation, anti-angiogenesis and other effects. For the patients of CRP with intractable bleeding, a prospective, open clinical trial will be carried out to observe the safety and effectiveness of thalidomide in treating hemorrhagic CRP.

Timeline

Start
2020-12-14
Primary completion
2022-07-30
Completion
2022-12-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Thalidomide Other / unclassified 50 mg Oral
Subject Thalidomide Other / unclassified 75 mg Oral

Indications